Study of [11C]CPPC as a Clinical PET Radioligand Biomarker of Microglial Activation in ALS

NCT05602142 | Not Yet Recruiting Phase 1 FDA Drug

• 2 other identifiers: IRB00343494W81XWH-22-1-0130
• Study Type: interventional
• Target: 20
• Locations: 0 countries
• Sites: N/A

Brief Summary

1. 1.Establish the safety and tolerability of the 5-cyano-N-(4-(4-\[11C\]Methylpiperazin-1-yl)-2-(Piperidin-1-yl)Phenyl)Furan-2-carboxamide (\[11C\]CPPC) PET radioligand in ALS patients and controls
2. 2.Examine whether \[11C\]CPPC PET uptake is elevated in brains of ALS patients and whether there is a correlation with clinical phenotype.
3. 3.Correlate \[11C\]CPPC PET imaging with other ALS outcome measures and biofluid biomarkers
4. 4.Examine longitudinal changes in \[11C\]CPPC PET imaging during disease course.

Conditions

ALS

Keywords

Biomarkers

Outcome Measures

Primary Outcomes (4)

• Safety of use of [11C]CPPC in patients with ALS as assessed by adverse events

  Safety of use of \[11C\]CPPC in positron emission tomography (PET) neuroimaging of patients with a diagnosis of ALS. Safety will be assessed by number of adverse events during and up to 180 days after the injection

  Up to 180 days after scan

• Safety of use of [11C]CPPC in patients with ALS as assessed by a change in neurological status

  Safety of use of \[11C\]CPPC in positron emission tomography (PET) neuroimaging of patients with a diagnosis of ALS. Safety will be assessed by neurological physical exam to determine if there is a change in the findings from baseline.

  Baseline and 180 days after scan

• Safety of use of [11C]CPPC in patients with ALS as assessed by a change in complete blood count (CBC) test

  Safety of use of \[11C\]CPPC in positron emission tomography (PET) neuroimaging of patients with a diagnosis of ALS. Safety will be assessed by monitoring of the complete blood count (CBC) for a change from baseline that is outside of the normal range.

  Baseline and 180 days after scan

• Safety of use of [11C]CPPC in patients with ALS as assessed by a change in complete metabolic panel (CMP) test

  Safety of use of \[11C\]CPPC in positron emission tomography (PET) neuroimaging of patients with a diagnosis of ALS. Safety will be assessed by a change in the CMP from baseline that is outside of the normal range.

  Baseline and 180 days after scan

Secondary Outcomes (1)

• Sensitivity of use of [11C]CPPC as assessed by a radiologist

  Up to 180 days after scan

Study Arms (1)

[11C]CPPC

EXPERIMENTAL

All participants will receive \[11C\]CPPC which is a radiotracer ligand that specifically binds to CSF1R.

Drug: [11C]CPPC PET ligand

Interventions

[11C]CPPC PET ligand DRUG

Radioactive PET ligand to determine microglia expression of colony stimulating factor 1 receptor (CSF1R).

Also known as: 5-cyano-N-(4-(4-[11C]methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl)furan-2-carboxamide

[11C]CPPC

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Have the ability to understand the requirements of the study, provide written informed consent, understand and provide written authorization for the use and disclosure of Protected Health Information (PHI) \[per Health Insurance Portability and Accountability Act (HIPAA) Privacy Ruling\] and comply with the study procedures.
• Men and women at least 18 years old.
• Male patients, who have not had a vasectomy and a confirmed zero sperm count, must agree for the duration of the study to:
• use a condom during sexual intercourse with female partners who are of reproductive potential AND to have female partners use an additional effective means of contraception (e.g., diaphragm plus spermicide, or oral contraceptives) OR
• male patient must agree to abstain from sexual intercourse during the study
• Women must have a negative serum pregnancy test and practice an acceptable method of contraception or be of non-childbearing potential (post-menopausal for at least 2 years or who have undergone hysterectomy, oophorectomy or surgical sterilization). Women must not be breastfeeding.
• Geographic accessibility to the study center and the ability to travel to the clinic for study visits.
• Presence of a willing and able caregiver.
• Diagnosis of ALS based on examination by the site PI, meeting El Escorial criteria for possible, laboratory-supported probable, probable or definite ALS or be a person without a diagnosis of ALS disorder.
• Vital capacity ≥ 50% of predicted normal for age, height and gender measured in the seated position and the ability to lie supine for a period of 1 hour.
• Agrees to the visit schedule as outlined in the informed consent.
• Pre-study labs within normal range, or if abnormal, deemed not clinically significant by the site investigator.

You may not qualify if:

• Weakness due to causes other than ALS.
• Receipt of any investigational drug, device or biologic within 10 days of administration of study compound.
• Use of anti-inflammatory medications, immunosuppressants, or benzodiazepines within 7 days of administration of study compound.
• Any concomitant medical disease or condition limiting the safety to participate including, but not limited to:
• Coagulopathy
• Active infection
• Any condition that the site PI feels may interfere with participation in the study.
• Inability to provide informed consent as determined by the site PI.
• Known clinical evidence of frontotemporal dementia.
• Inadequate family or caregiver support as determined by the site PI.
• Presence of any of the following conditions:
• Current drug abuse or alcoholism
• Unstable medical conditions
• Unstable psychiatric illness including psychosis and untreated major depression within 90 days of screening

Sponsors & Collaborators

• Johns Hopkins University: lead
• United States Department of Defense: collaborator

Study Officials

• Nicholas Maragakis, MD

  Johns Hopkins University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

JinAe Arneklev, CRNP

CONTACT

410-502-2932; jarnekl1@jhu.edu

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Disease group and healthy controls will receive the same drug

Study Record Dates

• First Submitted: October 21, 2022
• First Posted: November 1, 2022
• Study Start (Estimated): August 1, 2026
• Primary Completion (Estimated): January 1, 2027
• Study Completion (Estimated): July 1, 2027
• Last Updated: April 13, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share